Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.8.0.1
Commitments and Contingencies (Details) - USD ($)
 1 Months Ended 3 Months Ended
Dec. 13, 2017
Dec. 13, 2017
Aug. 04, 2016
Jun. 15, 2012
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Feb. 16, 2016
Commitments and Contingencies (Textual)                
Incurred expenses         $ 4,462,969 $ 4,573,502    
Accounts payable and accrued expenses         6,386,294   $ 4,650,088  
Oak Ridge National Laboratory [Member]                
Commitments and Contingencies (Textual)                
Purchase of materials $ 200,000 $ 200,000     100,000 100,000    
AbbVie Biotherapeutics Corp. [Member] | Phase 1 Clinical Trial of a licensed product [Member]                
Commitments and Contingencies (Textual)                
Accounts payable and accrued expenses         750,000      
AbbVie Biotherapeutics Corp. [Member] | Phase 2 Clinical Trial of a licensed product [Member]                
Commitments and Contingencies (Textual)                
Milestones Payments         750,000      
Medpace, Inc. [Member]                
Commitments and Contingencies (Textual)                
Total project estimated to cost               $ 7,200,000
Research and development costs         600,000 400,000    
George Clinical Services [Member]                
Commitments and Contingencies (Textual)                
Project estimated cost     $ 4,600,000          
Research and development costs         700,000 200,000    
License and Sponsored Research Agreement [Member] | Fred Hutchinson Cancer Research Center [Member]                
Commitments and Contingencies (Textual)                
Milestones Payments       $ 1,000,000        
Description of royalty payment       Royalty payments of 2% of net sales will be due to FHCRC.        
Incurred expenses         0 27,000    
Product Development and Patent License Agreement [Member] | AbbVie Biotherapeutics Corp. [Member]                
Commitments and Contingencies (Textual)                
License fee payment         3,000,000      
Milestones Payments         $ 7,750,000      
Description of royalty payment         The Company shall pay to AbbVie Biotherapeutics Corp. on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.      
Royalty of net sales percentage         12.00%      
First commercial sale period         12 years 6 months      
Goodwin Biotechnology Inc. [Member]                
Commitments and Contingencies (Textual)                
Research and development costs         $ 400,000 100,000    
Project remaining cost           $ 1,800,000